Vantis Vascular Secures $10 Million in Series B Funding

Vantis Vascular announced today the successful closure of its Series B-1 preferred funding round, securing $10 million.

Based in San Jose, California, Vantis’ recent fundraising efforts bring its total capital to $30 million. The company focuses on developing the CrossFast microcatheter guide extension system and the CrossShock intravascular lithotripsy (IVL) system. CrossFast is designed to facilitate faster, easier, and safer medical procedures.

The innovative DuoPro interlocking technology integrates the microcatheter with the outer delivery catheter, enhancing the functionality of CrossFast by boosting pushability and navigation efficiency.

This guide extension catheter is engineered to offer additional support, aiding device delivery in challenging anatomical areas and handling complex, high-risk cases. Vantis earned FDA clearance for CrossFast in October, with the system currently available in the U.S. on a limited basis, while a full launch is planned for the next year.

“We are thrilled to receive continued backing from a robust group of investors who share our vision of revolutionizing the execution of complex interventional procedures,” said Jason Turner, CEO of Vantis Vascular. “This funding represents a crucial step for Vantis, enabling ongoing product development, team expansion, and the initiation of U.S. commercialization of the CrossFast advanced delivery system for intricate high-risk PCI procedures.”